Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNNOVATE: Ibrutinib + Rituximab in Waldenström's Macroglobulinemia
NCT02165397Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- Jul 2014
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of ibrutinib in Waldenström's macroglobulinemia (WM), sponsored by Pharmacyclics. Started Jul 2014; status: completed.
02
Drugs
ibrutinib
03
Conditions
Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02165397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02165397.